LoxiGen, Inc. develops innovative cancer therapies targeting Lysyl Oxidases (LOX) in desmoplastic cancers or fibrosis-driven diseases.

LoxiGen, Inc. was founded by Dr. Ozgur Sahin with the aim to develop treatments for patients with unmet clinical need, thereby providing great benefits to patients without serious side effects.

LoxiGen’s current lead molecule opens up the desmoplastic stroma around the tumor and make the standard-of-care penetrate better in different solid tumors.